- Eli Lilly And Co LLY is set to invest $15 million in its small activating RNA (saRNA) partner, MiNA Therapeutics.
- The investment comes two months after Lilly agreed to pay $25 million upfront to work with MiNA on up to five targets.
- MiNA will use the money to advance its internal pipeline of saRNA therapeutics, led by a drug designed to cut immunosuppression by raising levels of the C/EBP-⍺ master regulator of myeloid cell differentiation.
- Price Action: LLY shares are up 0.05% at $234.07 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in